


Securities and Exchange Commissions  
Divisions of Corporate Finance  
450 Fifth Street  
Washington, D.C. 20549  
USA

5 March 2007  
DKGUJ/GUJ

Coloplast A/S  
Holtedam 1  
3050 Humlebæk  
Tel: +45 49 11 11 11  
www.coloplast.com  
CVR-nr. 69749917



5 March 2007

Gunilla Jensen  
Executive Secretary

Corporate Communications

Dir. tlf. +4549113621  
Mobil +4530853621  
Fax +4549111555  
dkguj@coloplast.com

Dear Sirs,


**SEC File Number 82-34793**

This information is furnished pursuant to Rule 12g3-2(b).

Please find enclosed information to the Copenhagen Stock Exchange  
Nos. 3/2007, 4/2007, and 5/2007.

**SUPPL**

Yours sincerely,  
Coloplast A/S

  
Gunilla Jensen  
Corp. Communications & IR

Encls.


**PROCESSED**

**MAR 20 2007**

**THOMSON  
FINANCIAL**

*B*  
*See 3/19*

**Stock Exchange Announcement no. 3/2007**  
**20 February 2007**



## **Coloplast divests its Brachytherapy business**

Coloplast has entered into a definitive agreement to divest its Brachytherapy business, acquired as part of the Mentor Urology business in June 2006, for approximately DKK 60m (USD 10.5m). The products divested are used for local radiotherapy treatment of prostate cancer. The transaction includes a stand-alone sales force and Coloplast's factory in Oklahoma, USA, also known as Mills Biopharmaceuticals LLC.

The purchaser of the Brachytherapy business is Brachysales Inc., a privately held company based in Santa Barbara, USA. The transaction is expected to close by June 2007, subject to specific closing conditions, including acquirer's financing and relevant governmental approvals. The transaction will have limited effect on Coloplast's Group results.

The Brachytherapy business falls outside Coloplast's strategy, both with respect to customer base, type of products, and production technology. Thus, the divestment is consistent with Coloplast's strategy towards 2012 to prioritize its three core businesses, Ostomy Care, Urology and Continence Care and Wound and Skin Care.

The results of the Brachytherapy business will be included in the interim financial statement due 15 May 2007, as net profit from discontinued operations. Comparative figures will be restated before the interim financial statement. As the Brachytherapy business accounts for approximately 1% of Coloplast Group revenue, the divestment does not cause Coloplast to change its expectations for 2006/07 nor the long-term objectives for 2012.

Sten Scheibye  
President, CEO

## **Further information**

### **Investors and financial analysts**

---

Jørgen Fischer Ravn  
Head of Investor relations  
Tel. +45 3085 1308  
E-mail: dkjfr@coloplast.com

---

### **Press and the media**

---

Jens Tovborg Jensen  
Head of Media relations  
Tel. +45 3085 1922  
E-mail: dkjto@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

**Stock Exchange Announcement no. 4/2007**  
**21 February 2007**

## **Coloplast is re-organising for future growth**

**Coloplast supports its long-term growth ambitions through a new organisational structure, which will strengthen innovation, sales and marketing activities.**

Coloplast's strategy towards 2012, "Investment in growth", was announced in November 2005 and Coloplast has taken several initiatives to increase the company's profitability and hence free resources for growth initiatives.

Our competitive strength and growth opportunities rely not only on the company's profitability, but equally on innovative skills and the strength of our customer relations. We have therefore performed an analysis of our activities in the areas of innovation, sales and marketing, which now leads to the implementation of a new organisational structure with the aim to accelerate growth. The new organisation will:


- Strengthen the link between customer understanding, market insight and product development
- Efficiently channel resources into growth initiatives
- Accelerate time-to-market, and free up resources to spend more time with customers
- Allow competence centre functions to obtain scale efficiencies, share skills and prevent duplication

A new global organisation along functional lines will replace the three product divisions and the six regional sales organisations will be replaced with four regional and three large country sales organisations.

The key changes are:

- Three new global units reporting to Executive Vice President and CCO Lars Rasmussen: 'Global Marketing, Global R&D and Commercial Excellence' will replace the three product divisions
- United Kingdom, Germany and France will report directly to the CCO, giving greater freedom and flexibility in these significant markets
- All other European countries will report to a new Region Europe creating greater opportunities to share learning's and best practice
- Region North America replaces Region Americas giving greater focus on the US and Canada
- A new Region for 'Emerging Markets' has been established, to concentrate on countries with high growth potential
- Region Asia-Pacific remains unchanged.

The new organisation and key positions are shown in the chart below.



The new organisation will be operational from 30 March 2007. As of 1 April 2007 Anne Mette Olesen, SVP of the Urology and Continence Care Division, will take over responsibility for Corporate HR from Bente Laursen, who will continue to work with Corporate HR tasks on a part-time basis.

The changes support Coloplast in achieving its long-term targets, but they do not affect our expectations for 2006/07. The current segmentation in the financial reporting will be maintained.

In connection with the implementation of the new organisation Coloplast has decided to postpone the establishment of regional shared service centres and the costs related to the implementation of the new organisation are therefore included in the existing allocation to restructurings in 2006/07.

Potential redundancies, e.g. in connection with staffing of the Global R&D and Global Marketing competence centre functions will to a large extent be offset by new positions in other functions. Net savings related to the restructuring are therefore negligible.

Sten Scheibye  
President, CEO

**Further information**

**Investors and financial analysts**

---

Jørgen Fischer Ravn  
Head of Investor relations  
Tel. +45 3085 1308  
E-mail: dkjfr@coloplast.com

---

**Press and the media**

---

Jens Tovborg Jensen  
Head of Media relations  
Tel. +45 3085 1922  
E-mail: dkjto@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

**Stock Exchange Announcement No. 5/2007**  
**5 March 2007**

## **Coloplast initiates share buy-back**

**As mentioned in the company's interim financial statements for Q1 2006/07, the Board of Directors of Coloplast has decided to initiate a share buy-back programme. The programme will comprise the purchase of own shares in the order of DKK 1 billion during 2007 and part of 2008. The programme will be implemented from 5 March 2007.**

The share buy-back programme is being launched for the purpose of adjusting the company's capital structure. Coloplast's target is to maintain a level of net debt representing 2-3½ times EBITDA. The buy-back programme is being launched within the scope of the existing authority granted by the shareholders at the Annual General Meeting in December 2006 for the repurchase of up to 10% of the company's share capital. The intention is to propose to the Annual General Meeting that the shares repurchased under the new programme will be cancelled.

A first buy-back programme within the scope of the authority is expected to be exercised in the period from 5 March 2007 to 15 August 2007. The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million. This programme is expected to be followed by an additional programme in August 2007.

The buy-back programme will be structured in compliance with the rules of Commission Regulation No. 2273/2003 of 22 December 2003, which ensure that the company is protected against violation of insider legislation in connection with the buy-back.

The company has entered into a contract with SEB Enskilda, in which SEB Enskilda agrees to act as lead manager of the buy-back programme. According to a separate contract concluded with the company, SEB Enskilda will purchase shares on behalf of Coloplast A/S. SEB Enskilda has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company with regard to whether, to what extent and at what times SEB Enskilda purchases shares in the company.

Coloplast is entitled to stop the repurchase during the life of the buy-back programme in the event that significant changes are recorded in the company's affairs or in the market. If the company decides to stop the repurchase, such a decision will be disclosed to the public by announcement to the Copenhagen Stock Exchange. SEB Enskilda will subsequently no longer be entitled to purchase shares in Coloplast A/S on behalf of the company.

The buy-back programme is subject to the following terms:

- The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million.
- The maximum number of shares to be acquired under the buy-back programme is 1,200,000 shares of DKK 5 each at a total nominal value of DKK 6,000,000, equivalent to 2.5% of the share capital of Coloplast A/S.

- The maximum number of shares to be purchased in the company per daily market session is 11,945, equivalent to 5% of the average volume of shares in the company traded on the Copenhagen Stock Exchange in February 2007.
- In connection with the execution of trades under the buy-back programme, no shares will be purchased at a price deviating more than 5% upwards or downwards from the average price quoted on the Copenhagen Stock Exchange at the time of acquisition. Moreover, during the life of the buy-back programme no shares will be purchased at a price exceeding the higher of the following two prices:
  - i) the price of the last independent trade and
  - ii) the highest current independent bid on the Copenhagen Stock Exchange.
- Details of all transactions executed under the buy-back programme will be publicly disclosed not later than the end of the seventh daily market session.

Sten Scheibye  
President, CEO

#### **Further information**

##### **Investors and financial analysts**

---

Lene Skole  
Executive Vice President, CFO  
Tel. + 45 4911 1665  
E-mail: dklsk@coloplast.com

---

##### **Press and the media**

---

Jens Tovborg Jensen  
Head of Media Relations  
Tel. + 45 3085 1922  
E-mail: dkjto@coloplast.com

This announcement is available in a Danish and an English version. In case of discrepancies, the Danish version will prevail.